These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8408185)

  • 1. In vitro studies on interaction of 4-hydroperoxyifosfamide and 2-mercaptoethanesulphonate in malignant gliomas.
    Jäger AH; Bogdahn U; Apfel R; Pfeufer B; Dekant A
    J Cancer Res Clin Oncol; 1993; 119(12):721-6. PubMed ID: 8408185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro studies on interaction of 4-hydroperoxy-ifosfamide and radiotherapy in malignant gliomas.
    Jäger AH; Bogdahn U; Pfeufer B; Richter J; Apfel R; Dekant A
    Anticancer Res; 1993; 13(6A):2221-7. PubMed ID: 8297137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro studies on drug interaction of ifosfamide and ACNU in primary and metastatic human brain tumours.
    Bogdahn U; Drenkard D; Lutz M; Apfel R; Behl C
    J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S157-63. PubMed ID: 1795006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna.
    Bokemeyer C; Schmoll HJ; Ludwig E; Harstrick A; Dunn T; Casper J
    Br J Cancer; 1994 May; 69(5):863-7. PubMed ID: 8180015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ifosfamide induced depletion of glutathione in human peripheral blood lymphocytes and protection by mesna.
    Meier T; Allenbacher A; Mueller E; Multhoff G; Botzler C; Wiesnet M; Issels R
    Anticancer Drugs; 1994 Aug; 5(4):403-9. PubMed ID: 7949243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.
    Dechant KL; Brogden RN; Pilkington T; Faulds D
    Drugs; 1991 Sep; 42(3):428-67. PubMed ID: 1720382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dithio-bis-mercaptoethanesulphonate (DIMESNA) does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in LLC-PK1 cells.
    Mohrmann M; Ansorge S; Schönfeld B; Brandis M
    Pediatr Nephrol; 1994 Aug; 8(4):458-65. PubMed ID: 7524598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifosfamide metabolites CAA, 4-OH-Ifo and Ifo-mustard reduce apical phosphate transport by changing NaPi-IIa in OK cells.
    Patzer L; Hernando N; Ziegler U; Beck-Schimmer B; Biber J; Murer H
    Kidney Int; 2006 Nov; 70(10):1725-34. PubMed ID: 17003823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
    Kurowski V; Wagner T
    Cancer Chemother Pharmacol; 1997; 39(5):431-9. PubMed ID: 9054957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
    Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesna inactivates platinum agents in vitro.
    Wolff JE; Egeler RM; Anderson R; Ujack E; Iceton S; Coppes MJ
    Anticancer Res; 1998; 18(6A):4077-81. PubMed ID: 9891448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary.
    Crotzer DR; Wolf JK; Gano JB; Gershenson DM; Levenback C
    Gynecol Oncol; 2007 May; 105(2):399-403. PubMed ID: 17292457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood. A Pediatric Oncology Group Study.
    Bernstein ML; Whitehead VM; Devine S; Grier H; Kung F; Krischer J; Dreyer Z; Bell B; Land V; Buchanan GR
    Cancer; 1993 Sep; 72(5):1790-4. PubMed ID: 8348510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
    Antman KH; Elias A; Ryan L
    Semin Oncol; 1990 Apr; 17(2 Suppl 4):68-73. PubMed ID: 2110386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous infusions of ifosfamide/mesna and perturbation of warfarin anticoagulant control.
    Hall G; Lind MJ; Huang M; Moore A; Gane A; Roberts JT; Cantwell BM
    Postgrad Med J; 1990 Oct; 66(780):860-1. PubMed ID: 2129174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma.
    Cantwell BM; Carmichael J; Ghani S; Harris AL
    Cancer Chemother Pharmacol; 1988; 21(1):49-52. PubMed ID: 3124971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ifosfamide-induced stomatocytosis and mesna-induced echinocytosis: influence on biorheological properties of blood.
    Reinhart WH; Baerlocher GM; Cerny T; Owen GR; Meiselman HJ; Beer JH
    Eur J Haematol; 1999 Apr; 62(4):223-30. PubMed ID: 10227455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide.
    Kuśnierczyk H; Konarski L; Kowalski P; Radzikowski C
    Arch Immunol Ther Exp (Warsz); 1997; 45(1):79-85. PubMed ID: 9090445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ifosfamide and mesna at high doses for the treatment of cancer of the cervix: a GETLAC study.
    Cervellino JC; Araujo CE; Pirisi C; Sanchez O; Brosto M; Rossi R
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S1-3. PubMed ID: 2112052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosing and side-effects of ifosfamide plus mesna.
    Brade WP; Herdrich K; Kachel-Fischer U; Araujo CE
    J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S164-86. PubMed ID: 1795007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.